Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients
Nadezda Petejova1, Arnost Martinek, Jana Zahalkova
1Department of Internal Medicine, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Czech Republic.
Aims:
To assess the influence of continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 mL/kg/h on vancomycin pharmacokinetics in critically ill septic patients with acute kidney injury (AKI).
Methods:
Seventeen adult septic patients with acute kidney injury treated with CVVH and vancomycin were included. All patients received first dose of 1.0 g intravenously followed by 1.0 g/12 h if not adjusted. In sixteen patients vancomycin was introduced on the day of the start of CRRT therapy. Blood samples and ultrafiltrates were obtained before and 0.5, 1, 6 and 12 h after vancomycin administration.
Results:
On the first day, the median total vancomycin clearance (Cltot) was 0.89 mL/min/kg (range 0.31 - 2.16). CRRT clearance accounted for around 50-60% of the total clearance of vancomycin found in a population with normal renal function (0.97 mL/min/kg). Vancomycin serum concentrations after the first dose were below the required target of 10 mg/L as early as 6 h in 10 patients, AUC0-24/MIC ≥ 400 ratio was achieved in 10 patients on the first day.
Conclusions:
CVVH at a filtration rate of 45 mL/kg/h leads to high and rapid extracorporeal removal of vancomycin in critically ill patients. Due to the rapid change in patient clinical status it was impossible to predict a fixed dosage regimen. We recommend blood sampling as early as 6 h after first vancomycin dose with maintenance dose based on vancomycin serum level monitoring.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Continuous Renal Replacement Therapy
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Estimation of k and VD of Aminoglycosides
Hemodialysis II: Procedure and Complications

